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RISK STRATIFICATION FOR OUTPATIENT PENICILLIN ALLERGY 
EVALUATIONS 
 
EMILY M. HUEBNER 
 
ABSTRACT 
Objectives: Penicillin allergies are the most commonly reported drug allergy. However, 
recent research has supported the concept that reported penicillin allergy does not equal 
true allergy. False penicillin allergies and associated alternative antibiotic use can result 
in inferior clinical outcomes. Determination of true versus self-reported allergy can be 
determined through skin testing to penicillin and oral challenge to amoxicillin.  
Penicillin allergy evaluations improve antibiotic utilization but penicillin skin testing 
(PST) requires more resources than oral amoxicillin challenge alone. Because amoxicillin 
challenge without preceding PST may be safe in low-risk patients, we assessed a risk 
stratification tool for outpatient penicillin allergy evaluations that stratify low-risk 
patients to receive amoxicillin challenge without prior skin testing.  
Methods: The patient population was identified using the Massachusetts General 
Hospital Allergy Associates clinic schedule in EPIC from the beginning of January 2017 
through the end of July 2018. Patients were classified into one of two evaluation methods 
based on allergy history, using the MGH Allergy Associates Outpatient Penicillin Allergy 
Pathway. Patients deemed low-risk were evaluated with direct 2-step oral amoxicillin 
challenge. Intermediate-risk patients were evaluated with PST and subsequent oral 
amoxicillin challenge. Skin testing (ST) was performed using epi-cutaneous prick tests 
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with a major and minor determinate of penicillin, histamine (positive) and saline 
(negative) controls, followed by intradermal injections of the same reagents. ST was 
followed by one oral dose of 500mg amoxicillin. Direct oral challenge involved doses of 
50mg of amoxicillin in the first step or 500mg of amoxicillin in the second step. These 
patients’ charts were retrospectively reviewed for information regarding the initial 
antibiotic allergic reaction, type of allergy testing administered, and outcomes of the 
outpatient allergy testing. Analysis was performed to assess and significant differences in 
patient characteristics, safety, and outcomes in patients given preceding skin testing or 
direct oral amoxicillin challenge. 
Results: Overall, 509 eligible patients were reviewed. Four hundred twenty-six patients 
underwent PST with subsequent oral amoxicillin challenge. The remaining 83 patients 
received direct, two-step oral amoxicillin challenge. Across both groups, 43 adverse drug 
reactions (ADRs) were observed, 26 of which were considered hypersensitivity reactions 
(HSRs). The proportion of patients in each testing group that experienced ADRs was near 
equal, 8.5% of the skin tested group and 8.4% of the direct challenge group. One patient 
in each group had an HSR requiring treatment with epinephrine. Using multivariate 
logarithmic analysis to evaluate potential predictors for ADRs and HSRs, female sex was 
the only variable associated with significant increased odds for an ADR. There were no 
significant findings for increased odds for HSRs, including evaluation method with direct 
drug challenge. The proportion of patients considered to have a true penicillin allergy was 
similar in the two groups. 
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Discussion: PST is a vitally important aspect of antibiotic stewardship, especially when 
conducted before antibiotic treatment is required. Though the standard procedure is skin 
testing with penicillin, followed by oral amoxicillin challenge, direct oral challenges can 
be considered for appropriately selected low-risk patients presenting for penicillin allergy 
evaluation.  PST is nonetheless advisable for patients with higher risk allergy histories, 
pregnant patients, and patients with tenuous cardiac or pulmonary status. 
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INTRODUCTION 
Penicillin History and Development 
Penicillin discovery and characteristics  
Though antibiotics in the form we recognize today were not discovered until the 20th 
century, the use of natural treatments for infections dates back to ancient Egypt, Greece, 
and China. There are records that document ancient healers applying moldy bread and 
poultices of moldy apple and barley to infected wounds to promote healing.44  
However, it was in 1928 that microbiologist and pharmacologist Sir Alexander Fleming 
unintentionally and formally discovered the first antibiotic, penicillin. His work to isolate 
the mold that grew on his petri dishes, the work of Howard Flory and Ernst Chain to 
purify penicillin 12 years later, and the human research subjects on whom they tested 
their isolations on created a clinical marvel and instantly changed infectious disease 
medicine. Doctors finally had solutions for their patients with rheumatic fever, 
pneumonia, and blood infections, and this wonder drug was discovered in time to save 
the lives of thousands of soldiers in World War II. It is prescribed even more often today 
to treat many ailments from minor illnesses to major infections. Without question, 
penicillin and its derivatives have been in the frontline of antibiotic therapy for nearly a 
century.  
Beta-lactam antibiotics and cross-reactivity 
With time, more became known about penicillin and its related structures. Penicillins are 
a family of broad-spectrum antibiotics belonging to the beta-lactam class. Beta-lactam 
antibiotics are named as such because their structures contain a beta-lactam ring, which 
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aids their function to prevent bacterial growth by interfering with peptidoglycans. 
Peptidoglycans are responsible for bacterial cell wall synthesis. Antibiotics belonging to 
the beta-lactam family are those such as penicillins, cephalosporins, monobactams, and 
carbapenems.30 The similar structures and R side chains of drugs in this class can lead to 
cross-reactivity in drug allergy, or a reaction to a drug because it shares a protein with the 
culprit drug.19 Because of this, patients with histories of cephalosporin allergies are also 
tested to penicillins, to assess any potential cross-reactivity depending on the side chain, 
as well as evaluate if penicillin or amoxicillin can be used in place of a cephalosporin for 
antibiotic treatment. 
Antibiotic resistance and significance for allergy testing 
Today, many decades after the development of penicillin, antibiotic resistance is a 
common topic. Antibiotic resistance is a clinical and public health crisis. The use of 
antibiotics perpetuates the production of antibiotic-resistant bacteria as antibiotics kill 
sensitive bacteria but leave behind the resistant bacteria that can multiply and spread. 
Inappropriate antibiotic use or overuse and the slow pace of novel drug development are 
partial causes for the sharp uptick in resistant strains of bacteria and infections and have 
led to the clinical discipline of antibiotic stewardship. Some methods of resistance 
involve the bacteria’s use of beta-lactamases, which are enzymes that cleave the 
antibiotic’s beta-lactam ring, disabling the feature of antibiotics that interact with 
peptidoglycan formation. This is the method used by common infections such as 
Staphylococcus aureus, Neisseria gonorrhoeae, and Escherichia coli. While there are 
also causes of antibiotic resistance that stem from resistance-conferring genes and 
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biosynthetic antibiotic genes37, we must try to reduce the “user error” impact on antibiotic 
resistance. Penicillin allergy testing and antibiotic stewardship programs are effective 
approaches to ensure appropriate use of antibiotics and combat antibiotic resistance. The 
Infectious Disease Society of America, the Society for Healthcare Epidemiology of 
America, and the Pediatric Infectious Disease Society have created a set of guidelines to 
help institutions that are interested in implementing an antibiotic stewardship program 
(ASP). These guidelines have suggestions for intervention, optimization, diagnostics, and 
measurement to ensure best practice based on various hospital or institutional policies3.  
Drug Allergy Evaluation 
Penicillin skin testing 
Dr. Bernard Levine and Dr. Charles Parker separately and concurrently pioneered the use 
of penicillin skin testing (PST) in the 1960s. Their groups determined its safety, efficacy, 
and negative predictive value. Levine’s group utilized benzylpenicilloyl-polylysine 
(BPL) and a minor determinant mixture (MDM) to assess 218 patients with infectious 
diseases or fevers and a history of penicillin allergy. They concluded that patients that 
skin tested negative to both BPL and MDM were at very low risk for an immediate 
hypersensitivity reaction and a positive skin test was associated with high risk for 
immediate reaction to penicillin.25 Around the same time, Parker and his colleagues were 
also studying the immunochemical basis of PST. This group found that testing results 
varied greatly depending on patient population and the penicillin reagent was used. Their 
patients that were skin tested with penicilloyl-polylysine 2-2.5 months after their allergic 
reaction had a much higher reaction rate than patients with more recent reaction 
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histories.32 However, these patients seldom had positive skin tests to penicillin and its 
derivatives other than penicilloyl-polylysine. This study helped provide the basis of the 
use of penicilloyl-polylysine as an efficacious reagent in evaluating suspected penicillin 
allergies and preventing more serious hypersensitivity reactions. 
Penicillin allergy prevalence 
Penicillin is noted to be the most common drug allergy for Americans, with 10% of the 
population noting a penicillin allergy.1, 34, 45 This number is even larger amongst 
hospitalized patients, at around 15%.24, 27 However, 90% of people with a self-reported 
penicillin allergy are not truly allergic based on allergy testing, thus avoiding an effective 
and inexpensive medication for seemingly no reason. Therefore, it is maintained that a 
large proportion of anecdotally allergic patients can safely receive penicillin antibiotics.31 
This discrepancy between reported and true penicillin allergies can stem from a remote 
history that is poorly recalled, the characterization of a reaction as an allergy despite non-
IgE hypersensitivity (intolerance symptoms such as nausea, vomiting, diarrhea), or loss 
of hypersensitivity with time. Addressing unverified beta-lactam allergies is important for 
antibiotic stewardship and quality improvement. Patients with reported and labeled 
penicillin allergies require treatment with second-line antibiotics, such as cephalosporins, 
carbapenems, macrolides, and fluoroquinolones.28 Treatment with these antibiotics has 
several disadvantages for the patients. They are more expensive per dose4, associated 
with more severe adverse events29, can require longer duration of treatment to achieve 
desired effect4, are broader spectrum, and have inferior clinical.6, 7   
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Unverified beta-lactam allergies interfere with optimal care of infections in the hospital.  
Guidelines exist that indicate vancomycin is a sub-optimal antibiotic compared to beta-
lactams for MSSA treatment. In methicillin-sensitive Staphylococcus aureus (MSSA) 
bacteremia, giving vancomycin as an alternative drug to a beta-lactam results in more 
treatment failure (15% vs 9%) and death (18% vs 7%) than using the penicillin allergy 
history to guide treatment with an indicated beta-lactam.6 A penicillin allergy history was 
the strongest negative predictor of receiving optimal therapy for patients with MSSA 
bacteremia. Patients with gram negative bacteremia treated with a beta-lactam alternative 
because of their allergy history experienced 10% more treatment failures.20  Although 
aztreonam is often used for inpatient gram-negative bacterial infections in patients with 
beta-lactam allergy histories because there is no risk of beta-lactam cross-reactivity, it is 
less effective against Pseudomonas Spp.17 and is nearly double the cost per day compared 
to the beta-lactams cefepime or ceftazidime.29 The high cost of aztreonam explains some 
of the higher costs observed for inpatients with reported penicillin allergy. 
 
In 2016, the American Academy of Allergy Asthma and Immunology released an official 
position statement that penicillin allergy evaluation should be performed routinely in 
patients with self-reported penicillin allergy.33 Despite this, many health care facilities are 
unable to systematically implement a beta-lactam allergy evaluation program. 
Cost of penicillin allergy 
There is strong evidence to support that inappropriate use of alternative antibiotics due to 
a reported penicillin allergy leads to increased spending for institutions and patients, 
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alike. A study in a large tertiary academic center calculated costs of treatment for patients 
that would have received a beta-lactam antibiotic, had it not been for their reported 
penicillin allergy, and received an alternative antibiotic in its place.34 This group 
estimated the daily cost of a variety of beta-lactam and alternative antibiotics and 
assessed the days of treatment to determine a total additional cost of $15,672 due to the 
use of alternative antibiotics when beta-lactam use was indicated. A study of a pediatric 
cohort of 100 patients found that appropriate de-labeling and subsequent prescription 
with penicillin led to cost savings of $1,812 with a total potential savings of $192,223 for 
the pediatric emergency department.43 A PST guideline in a large teaching hospital 
allowed for beta-lactam antibiotic treatment of 146 patients with reported penicillin 
allergy.36 This led to $82,000 in total savings from clearing the drug allergy, including 
cost of altering therapy after a negative PST and including cost of PST. This savings is 
equal to $225 per patient. These results were not limited to academic research centers, as 
similar savings were also found at community medical centers. A study at a tertiary 
referral community teaching facility implemented a multi-pronged approach to penicillin 
allergy evaluation, utilizing a prescription screening tool, education, and clinical decision 
support found an estimated cost avoidance of $60,000-$100,000, depending on the 
antibiotic selected.38 An antibiotic stewardship initiative identified inpatients receiving 
aztreonam with a penicillin allergy label and allowed the pharmacy staff to make therapy 
recommendations on the patient’s allergy history. Patients with mild or remote allergy 
histories were recommended to undergo PST, none of which had reactions to PST and 
subsequently received BLAs during their hospital stay. This led to a significant reduction 
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in aztreonam expenditure and annual savings of $28,134 based on hospital acquisition 
cost.13 Implementation of another pharmacist-led PST initiative led to estimated savings 
of approximately $314.75 per patient and an expected total cost savings of approximately 
$7554.08.21 These cost savings were found by calculating the difference between the 
costs of initially prescribed therapy and the therapy post-PST multiplied by days of 
therapy. Another study in a community teaching hospital retrospectively reviewed the 
reduction in cost following PST. They found that switching 37 patients to a beta-lactam 
antibiotic led to total cost savings of $11,005, or $297 per patient. Finally, a study was 
conducted at Massachusetts General Hospital (MGH) to assess the cost of penicillin 
allergy evaluation. This analysis took into consideration the personnel costs, clinic or 
space costs, and costs of the consumables used in penicillin allergy evaluation and 
testing.4 They calculated the cost of the standard penicillin allergy evaluation, consisting 
of penicillin reagents, amoxicillin doses, time in the clinic, and personnel compensation, 
to be $220. If no skin testing was required, the cost of evaluation was just $84. It would 
be very beneficial for patients with low-risk allergy histories to receive less expensive 
allergy testing, without compromising safety and efficacy. It is also clearly reported that 
cost reduction is a direct result of implementing penicillin allergy testing. This will 
hopefully encourage the incorporation of PST programs into institutions where they do 
not exist yet. 
Penicillin pathways: methods and settings 
There has been significant exploration of various penicillin allergy evaluation pathways. 
The bases of these pathways vary, from those that place emphasis more strongly on drug 
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allergy history to conduct risk-stratification, to those more purely focused on PSTs for all 
penicillin allergic patients. More recently, interprofessional programs have been piloted 
that utilize a comprehensive approach to allergy testing. Some designs might be more 
efficacious in one setting than another (large centers versus small centers, academic 
versus community, inpatient vs. outpatient, etc.) so studies such as these are of great use 
when institutions are exploring options for penicillin allergy testing programs.  
History-based pathways 
The drug allergy history alone is a powerful tool that can be used to improve antibiotic 
prescribing. Some institutions have developed pathways that risk-stratify based on the 
characteristics of the patient’s historical drug reaction. Several of theses studies utilized 
the pharmacy staff, identifying patients when certain antibiotics were ordered through the 
pharmacy. Pharmacists were also key collaborators with varied roles that included: 
creating patient tracking lists, intercepting antibiotic orders, educating patients/providers, 
taking allergy histories, and performing PSTs. Many pharmacist-led studies also shared a 
common goal of reducing aztreonam usage in the hospital. Phan et al. implemented a 
pharmacist-run initiative that identified patients with an aztreonam order. They educated 
pharmacists to clarify self-reported penicillin allergies when they received an order for 
aztreonam, then they would switch the order from aztreonam to a cephalosporin. The 
second part of the initiative was the development of a penicillin guidance pocket card that 
was distributed hospital-wide. This initiative improved clinical response rate from 83.6% 
pre-implementation to 91.4% post-implementation. Staicu et al. implemented a 
multipronged approach consisting of a PST allergy screening tool, education, clinical 
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decision support, and identified a patient cohort through review aztreonam orders sent to 
the pharmacy.38 This intervention reduced both total days of aztreonam therapy by 5.1 
days and days of inappropriate use of aztreonam by 3.2 days-per 1,000 patient days in the 
post-intervention group. Estep et al. created an Antimicrobial Stewardship Quality 
Initiative (ASQI) that involved EMR and interviewing of the patient’s family, if feasible, 
to produce a pharmacy evaluation and potentially alter the aztreonam order.13 34.6% of 
patients were switched to beta-lactam antibiotics (BLAs) post-implementation of this 
initiative with no adverse effects associated with BLAs.  
PST-based pathways 
PSTs require more resources and time than drug challenges. Time is required to prepare 
the reagents of Penicillin G, minor determinants, or ampicillin, and additional time is 
required to perform and interpret the test by the provider or relevant personnel. However, 
despite potential complexities, PST was the primary allergy intervention in the majority 
of beta-lactam allergy pathway studies. The selection process was potentially because of 
volume considerations. For example, we estimated that Massachusetts General Hospital 
(MGH) would need to perform over 60 PSTs per week to capture all inpatients with 
penicillin allergy histories on antibiotics.9  Patient selection might have also been 
performed to optimize skin testing resources and/or improve antibiotic stewardship 
outcomes. For example, capturing patients most likely to immediately benefit from a 
negative PST15 including those with an immediate need for optimal therapy or others 
whose underlying comorbidities predict future antibiotic need and could be tested semi-
 10 
electively while inpatient. Patient selection relied on antibiotic data, microbiology 
culture-data, or specialist expertise.  
Although there were some PSTs performed for inpatients, it was used less commonly 
than other pathways in the inpatient setting due to a primary outcome often being a 
universal hospital priority of reduction in length of hospital stay. That said, in a study on 
an inpatient pediatric population, patients with an antibiotic allergy, 85% of which were 
beta-lactam allergies, had longer hospital stays by 1.5 days.26 Therefore, the pay-off for 
implementing a PST pathway may reduce hospital stay, despite requiring extra time for 
evaluation. PST-based pathways have generally captured up to 20% of PST eligible 
inpatients.9, 10 However, PST was the pathway used for some earlier inpatient studies.  
Others have taken slightly different approaches at identifying patients who may benefit 
from PCN PST as part of antibiotic stewardship. A study in 1999 utilized a pharmacy 
search function to identify patients with a penicillin allergy. Their pathway resulted in 
BLA use increase from 36% prior to PST pathway use up to 82% post-implementation 
and avoided 46 patient-days of vancomycin use.15 In 2000, Arroliga et al. implemented a 
prospective PST pathway in the ICU and reported 10 of 21, or 48%, of patients were 
treated with a penicillin when the prior antibiotics had been ciprofloxacin (5), 
clindamycin (2), imipenem (2), and erythromycin (1).2 Of 100 patients in their follow up 
study, they reported 38 patients received an antibiotic, 31 (82%) of whom received a 
beta-lactam. The prior antibiotics for the 100 patients were vancomycin (73), quinolones 
(27), a third-generation cephalosporin (11), and antibiotics such as clindamycin or 
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metronidazole (6). Chen et al. reported 77 of the 223 (34%) patients with negative skin 
tests were switched to a penicillin or cephalosporin, and 8 patients were discharged on 
beta-lactam treatment.10 After testing, they noted a decrease in active orders for 
vancomycin, clindamycin, fluoroquinolones, carbapenems and aztreonam. At MGH, 
Blumenthal et al. reported unadjusted beta-lactam use increased from 50% to 60% but 
adjusted increased 570%, and in patients being discharged, the adjusted beta-lactam use 
was 250%.9 This was the result of a computerized guideline that would guide beta-lactam 
use in medical inpatients with a listed penicillin allergy by grouping allergic reactions 
into hypersensitivity type, then recommending risk and dosage. Chen et al. reported that 
penicillins increased from 0.32 to 0.71 administrations per patient day, 58% increased 
penicillin exposure, and aztreonam use declined from 2.54 to 1.47 administrations per 
1000 patient-days after the implementation of a clinical decision support tool.11 These 
studies demonstrate the safety and importance of PSTs and clinical support guidelines to 
empower non-allergy physicians to make antibiotic prescribing decisions and allow 
patients to safely receive beta-lactam antibiotics.  
However, there are also other negative consequences to false penicillin allergy labels that 
go further than antibiotic stewardship. A population based matched cohort study at MGH 
found that inpatients with reported penicillin allergy have an increased risk of methicillin 
resistant Staphylococcus aureus and Clostridium difficile that are modifiable through 
changes in antibiotic choice.5 Another study from MGH evaluated the impact of reported 
penicillin allergies on the development of surgical site infections (SSIs).7 Surgery patients 
that have undergone procedures such as an arthroplasty, hysterectomy, colon surgery, or 
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artery bypass graft surgery were retrospectively reviewed for development of an SSI and 
choice of perioperative antibiotics. Two hundred forty one of the 922 patients (26.1%) 
with a reported penicillin allergy developed an SSI. This group used multivariate logistic 
regression to find that patients reporting a PCN allergy had 50% increased odds of an 
SSI.  
Many of the incident allergic reactions for our patient cohort occurred when the patients 
were infants or children. Reactions of any kind in children are always of concern to 
parents and providers, but it is important to find the difference between appropriate 
avoidance and false culprits. There have been a few studies performed in the pediatric 
population to assess penicillin allergies in various settings, inpatient, emergency 
department, etc. One specific pediatric study evaluated penicillin allergic patients in the 
emergency department. They categorized patients by risk based on reaction symptoms 
and performed PST on 100 low-risk patients, all of which were negative for true 
penicillin allergy.42 These same patients were then followed up by phone within a year of 
their negative allergy testing. There were 46 prescriptions for antibiotics for 36 of these 
patients reported by a primary care provider or the parent(s), 58% of which were 
penicillin or penicillin derivatives. Only one child developed a minor rash, there were no 
serious adverse events reported.43 PST is a safe way to evaluate immediate-type 
hypersensitivity to penicillins and can be safely implemented in a variety of settings to 
assess penicillin allergy and increase appropriate antibiotic use.    
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Interprofessional initiatives 
Different specialties and types of care centers warrant different approaches to address 
antibiotic stewardship. Ready access to allergy consultation is a limitation for many 
institutions as allergy testing requires specialized training or a consult from an 
Allergy/Immunology specialist and patients often must be referred to larger medical 
centers for allergy testing. However, recent studies have been conducted to determine the 
feasibility of increasing recognition of relevant allergy evaluation, PST prevalence, and 
allergy de-labeling by other specialists in various types of institutions (academic, 
community, tertiary, outpatient) from a workforce and economic standpoint.20 Successful 
risk-stratification and clinical support guidelines have been researched in 
interprofessional, trainee-led, and specialty-specific settings. As an example of 
interprofessional collaboration, a community hospital developed a guideline generated 
from a collaboration between allergy and infectious disease physicians resulting in 
posters and pocket cards that were disseminated to house staff.14 The cards contained an 
evaluation pathway to allow physicians to determine when allergy testing, performed by 
an allergy consult, was warranted. This initiative increased appropriate skin testing from 
17% to 64%. In a similar effort, a large urban tertiary medical center successfully piloted 
an Infectious Disease (ID)-led PST program, that was managed by ID fellows with 
support from ID physicians. This pilot study demonstrated that with appropriate training 
and experience, a PST program is feasible in institutions that lack access to board 
certified allergists and immunologists.16 Though common in outpatient and hospital 
settings, penicillin allergy evaluation pathways have rarely been evaluated for feasibility 
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in emergency departments. Raja et al. conducted a study of 150 patients that presented to 
the emergency department (ED) with a listed penicillin allergy.35 ED physicians were 
trained by allergists conducted skin testing and allergy evaluation in the ED. Their study 
found that 91% of evaluated patients did not have an IgE-mediated allergy and their 
allergy was removed from their chart. The authors concluded that incorporating penicillin 
allergy testing is feasible in the ED and could potentially avoid inappropriate antibiotic 
use. 
Direct Amoxicillin Challenge 
The reagents used in PST are expensive4, in contrast, amoxicillin is relatively inexpensive 
and stocked in most pharmacies. PST, 1-step oral amoxicillin challenge, required 
personnel, and cost of space was found to cost approximately $220 per test at MGH, 
whereas just 2-step oral amoxicillin challenge without PST was approximately $84 per 
test.4 The cost per test for skin testing consumables and oral challenge was $114.09, 
whereas the cost per dose of amoxicillin was just $0.47. Direct oral challenge without 
preceding skin testing may also increase utilization by physicians other than allergists, as 
the administration of oral antibiotics and subsequent monitoring can be safely monitored 
without oversight by a board-certified allergist. This could further reduce the cost of 
allergy evaluation by reducing the involvement and cost of additional personnel. The 
ability of hospitals or care centers to perform inexpensive amoxicillin challenge without 
preceding skin testing could increase the ease of adding a penicillin testing service. Some 
studies have been performed to evaluate the appropriateness and success of direct oral 
amoxicillin challenge. In 2017, a cohort from the Marine Corps Recruit Depot in San 
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Diego, California tested a streamlined penicillin allergy testing method involving direct 
amoxicillin challenge.41 Due to the lack of time to complete allergy testing in the 
traditional method (skin testing with major and minor penicillin determinants followed by 
oral amoxicillin challenge) some recruits were given oral amoxicillin challenge without 
preceding skin testing. Four hundred two recruits were involved, 328 recruits went 
directly to amoxicillin challenge and 74 had skin testing in addition to amoxicillin 
challenge, the latter group had more severe allergy histories. The direct challenge caused 
objective reactions in only 5 (1.5%) patients. No recruits in the skin tested group had any 
reaction. Kuruvilla et al. created a penicillin evaluation protocol based on evidence of 
safe oral challenge without antecedent skin testing in low-risk patients.22 Both studies 
concluded that direct oral amoxicillin challenge may be a safe, efficient way to rule out 
penicillin allergy when resources and time are limited.  
 
The concept of direct amoxicillin challenge is starting to be researched more intensively 
in acute care settings, as well. A pediatric cohort that presented in the emergency 
department with reported penicillin allergy was immediately testing to oral amoxicillin, a 
negative immediate test meant the patients could participate in a 5-day drug provocation 
test to amoxicillin, with the first dose taken in the presence of a provider to assess any 
immediate reactions.23 Of the 130 children tested, 3 had positive immediate challenge, 3 
had positive nonimmediate challenge and 2 had indeterminant tests. The 122 patients 
with negative tests were followed up after 2 years to determine if antibiotics had been 
used since their challenge. 75 of the 122 had used antibiotics since with only one patient 
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refusing to use amoxicillin out of fear of a reaction. This study showed that a 5-day 
challenge is a safe way to rule out penicillin allergy in a pediatric population. Using a 
cohort of patients that had a history of non-immediate reactions to penicillin, Confino-
cohen et al. hypothesized that a 5-day challenge without preceding skin testing could 
safely allow for removal of an allergy label.12 They conducted skin testing to use as a 
comparative variable against the outcomes of the oral challenge. Patients received a 
tenth-dose and a full dose in the allergy clinic, if no reaction occurred, the patients could 
take the medication home and continue taking a full dose each day for 4 more days. Four 
hundred seventeen patients completed the full 5-day challenge and 44 patients partially 
completed the challenge, for non-allergic reasons, all without complications. Thirty 
patients experienced reactions at some stage of the home challenge. All of these results 
were not related or predicted by their skin testing results. Though these extended, at-
home studies were efficacious at removing false penicillin allergy labels and potentially 
assured both pediatric patients and their parents that it is safe to take amoxicillin, 
extended use of antibiotics without a clinical indication is controversial. The prolonged 
use of antibiotics without indication could be considered antibiotic overuse or misuse and 
could contribute to antibiotic resistance.  
In addition to researching the safety and efficacy of direct oral challenges, a group 
recently evaluated whether all reactions observed during allergy evaluation are true 
hypersensitivities. Iammatteo et al. conducted a single blind, placebo-controlled trial with 
direct oral challenge to amoxicillin. Their trial resulted in 31 out of 120 patients having 
reactions to the 2-step challenge.18 However, 16 of the 31 reactions were in the placebo 
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arm. This study’s outcome was very intriguing because it demonstrates that reactions 
observed were related to factors other than immediate-type hypersensitivity. These 
studies similarly concluded that direct oral amoxicillin challenge is a safe and effective 
way to evaluate patients with isolated reactions, such as gastrointestinal symptoms, 
reactions greater than 10 years prior to allergy testing, or non-immediate reactions, 
depending on the patient cohorts. This supports the use of our risk-stratification pathway 
in our outpatient penicillin allergy clinic, specifically to have our low-risk patients 
proceed to two-step amoxicillin challenge. 
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METHODS 
 
Study Population and Eligibility 
 We prospectively identified allergy patients coming into the outpatient allergy 
clinic at Massachusetts General Hospital from January 2017 through July 2018. Patients 
being seen in the allergy clinic may have been seen for acute drug allergy evaluation in 
the setting of pregnancy or cardiothoracic surgery, or to clarify an allergy without 
impending antibiotic treatment. No patients were evaluated in the clinic if their allergy 
history would be categorized as high-risk (Figure 1). Patients were excluded if their 
testing was incomplete. For example, if they only completed skin testing without 
subsequent oral challenge or if they only completed the first part of their oral challenge. 
After the completion of the patients’ allergy appointments, Electronic Health Records 
(EHRs) were reviewed for all variables relating to penicillin drug allergy. We identified 
patient demographics (age, sex, self-reported race), allergy histories, penicillin allergy 
evaluation method, and outcome, considering both adverse drug reactions (ADRs, any 
symptoms or signs reported by the patient) and hypersensitivity reactions (HSRs). To 
determine HSRs, two drug allergy specialists independently reviewed all ADRs and made 
a judgement about whether the symptoms and course were a likely HSR. All patients 
with objective cutaneous signs or treated with anti-allergy medications were considered 
to have had an HSR. We also recorded whether a patient’s antibiotic allergy label was 
removed following negative skin testing. If a patient was not appropriately de-labeled, a 
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reason was sought and recorded. For patients that were de-labeled, their charts were 
reviewed 6 months after allergy testing to assess if their allergy had been re-labeled.   
Guideline and Safety 
The Outpatient Penicillin Allergy Pathway (Figure 1) was utilized in the MGH outpatient 
allergy clinic to risk stratify patients based on their historical allergic reaction. Their 
historic reaction was either noted in the EHR or was reported anecdotally by the patient 
during their appointment. Using the pathway, patients deemed intermediate-risk 
underwent skin testing with a major penicillin determinate, benzylpenicilloyl-polylysine 
(Pre-Pen®) and a minor penicillin determinate, Penicillin G (PFIZERPEN®), followed 
by oral challenge with amoxicillin.  
Skin Testing and Challenge Procedures 
Skin testing is a two-part procedure (Figure 2). The first step is an epicutaneous method 
(Figure 3): scratching the surface of the skin, typically on the inner forearm, and placing 
droplets of the penicillin determinates next to histamine (positive) and saline (negative) 
controls. Patients are observed for 15 minutes following skin prick testing. If no reaction 
to skin testing occurs, patients proceed to the next step which is the intradermal testing, 
performed by injecting small blebs of the same benzylpenicilloyl-polylysine, penicillin G, 
histamine, and saline, typically on the upper arm. Patients are again observed for 15 
minutes. Intermediate-risk patients with negative skin testing would then be given an oral 
dose of 500mg amoxicillin and be observed for one hour. Patients considered low-risk 
proceeded to direct oral amoxicillin challenge in a two-step process. They are first given 
a dose of 50mg and observed for 30 minutes. If no reaction occurs or if a mild reaction 
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occurs, but it’s deemed safe by an allergy physician, they continue to receive a dose of 
500mg of amoxicillin and are observed for 60 minutes. The dose of oral amoxicillin was 
appropriately adjusted for pediatric patients based on patient weight.  
Data Analysis 
After data collection, the historical and test reactions were compared for low risk versus 
intermediate risk groups. Data was analyzed to determine safety of direct oral amoxicillin 
challenge. Demographic data in Tables 1 and 2 were reported as means with standard 
deviations or as counts with percentages. Continuous variables are presented as means 
with standard deviations and analyzed statistically by T-test, a parametric statistical tool. 
Categorical variables are categorized as nominal, such as race, reaction system, and 
analyzed statistically by Fisher’s exact test when the sample size is less than 30, or by 
Chi-square test when the sample size is greater than or equal to 30. Two-sided P values 
less than .05 were considered significant. We performed statistical analysis using R 
statistical software.   
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Figure 1. Outpatient Penicillin Allergy Pathway utilized by Massachusetts General 
Hospital Allergy Associates. This figure was created by the allergists in our research and 
clinical care group. This pathway utilizes the patient’s allergy history and description of 
the reaction to risk-stratify the patient into low-, intermediate-, or high-risk. This pathway 
was used for the patients described in this study. 
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Figure 2. Massachusetts General Hospital beta-lactam skin testing sheet. Skin testing 
sheets are developed by the allergy clinic based on the most recent literature published in 
medical journals. These are the concentrations and methods used for skin tested patients 
described in this study.
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Figure 3. Images of Penicillin Allergy Skin Testing. The MGH allergy clinic uses these 
methods to skin test drug allergy patients.8, 39 
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RESULTS 
Description and Comparison of Variables in the Study Population 
Of 509 patients evaluated for penicillin allergies, 426 (83.7%) were evaluated 
using skin testing followed by oral challenge (if skin testing was negative), and 83 
patients (16.3%) received direct oral challenges. 369 (72.5%) of patients were female and 
439 (86.2%) were white.  Other racial groups included Asian (4.3%), Hispanic (3.3%), 
and Black (2.2%).  184 patients (36.1%), were only allergic to penicillin, however, 114 
(22.4%) had just one other drug allergy, 73 (14.3%) had two other drug allergies, 44 
(8.6%) had three other drug allergies, and 94 (18.5%) had four or more other drug 
allergies (Table 1). The median number of drug allergies was 1. Penicillin or penicillins 
were the culprit drug for 352 patients (69.2%), 121 (23.8%) were allergic to amoxicillin, 
5 to ampicillin, and 3 to piperacillin. The remaining 17 patients (3.3%) had allergies to a 
cephalosporin.  For 11 patients (2.2%), the causative penicillin was not known. The 
majority of reported reactions were cutaneous (n=401, 72.5%) with respiratory symptoms 
(5.6%) and gastrointestinal symptoms (2.9%) also documented. 48 patients (8.7%) had a 
history angioedema. The reaction was unknown in 57 (10.3%). Most commonly, 
historical reactions were treated with antihistamines (10.2%). Some were treated with 
steroids (2.3%) or medical care in the emergency department or hospitalization (2.1%). 
Fluids were administered in just one case and other medications such as anti-vertigo 
medication or NSAIDs were given in 3 cases. Epinephrine treatment was definitely given 
for historical reactions for 6 patients (1.2%). The majority of patients (n=433, 83.4%) had 
unknown forms of treatment or no treatment. The time from the historical reaction to the 
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allergy testing appointment was unknown in 102 (20.0%) patients. There were 407 
reactions with known timing, most occurred more than 10 years prior to the evaluation 
(n=370, 72.7%) and are considered “remote”, but 37 patients (7.3%) presented within 12 
months of their reaction (Table 2).   
Comparison of Safety and Efficacy Between Testing Groups 
Of 426 patients who received PST, 66 (15.5%) were pre-cardiac surgery patients and 32 
(7.5%) were pregnant. All 426 patients had negative skin testing and were subsequently 
challenged to amoxicillin.  There were 36 ADRs (8.5%) experienced by skin tested 
patients, of which 21 (58.3%) were HSRs (Table 3). The 15 non-HSRs included mild 
pruritus, difficulty swallowing or sensations of throat swelling, reported flushing, and 
chest discomfort. Fifteen of the 21 HSRs (71.4%) were immediate and occured during 
observation in the clinic. The remaining 6 HSRs (28.6%) were delayed and reported to 
the clinic the evening of or days following allergy evaluation. There was 1 (4.8%) HSR 
that required treatment with epinephrine.  This patient had a penicillin rash history and 
developed dizziness, nausea, erythema, paleness, and hypertension (155/85mmHg) 10 
minutes after ingesting amoxicillin 500mg.  Their treatments included 0.3 mg IM 
epinephrine, 25mg diphenhydramine PO, and 40mg prednisone PO.  A second dose of 
epinephrine IM was given for rigors and throat tightness, and symptoms improved 90 
minutes later. Only 9 of the 21 patients (42.9%) with HSRs were deemed “positive” for 
penicillin allergy, some requiring the use of courses of steroids and antihistamines. The 
remaining 12 patients (57.1%) who experienced HSRs had very mild symptoms that 
resolved without intervention in 7 cases and required only a single dose of antihistamine 
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in the remaining 5 cases. Of 83 (16.3%) patients who were deemed low risk and received 
the direct amoxicillin challenge, 7 had an ADR (8.4%) of which 5 (71.4%) were 
determined to be HSRs. There was 1 (20.0%) HSR that required epinephrine. The patient 
who required epinephrine had a history of idiopathic anaphylaxis and a remote rash to 
penicillin. Fifteen minutes after the 500mg dose of amoxicillin, they developed facial 
hives and hypertension (157/93 mmHg) and progressed to involve throat itching and 
abdominal pain despite 20mg cetirizine PO.  Treatment with 0.3 mg IM epinephrine 
resulted in symptom resolution over the next hour. Of these 5 direct challenge patients 
that experienced HSRs, only 3 were deemed “positive” due to treatment with steroids 
and/or antihistamines. Both ADRs and HSRs were equally prevalent in the skin tested 
and oral challenge groups, at 8.5% vs 8.4% and 4.9% and 6.0%, respectively. The signs 
and symptoms were similar between the two groups. The reactions for direct challenge 
patients were slightly more often treated with antihistamines, corticosteroids, and 
epinephrine than the skin testing patients. In summary, there was no difference in 
reaction frequency (p=0.30), epinephrine use (p=0.35), or subjective symptom frequency 
(p=0.37) comparing penicillin allergy evaluation methods.   
Comparison of Test HSRs with Historical Reactions 
We conducted a multivariate analysis to determine if there were any predominant 
predictors of ADRs or HSRs. We assessed factors that have historically been found to 
increase likelihood of a reaction during allergy testing, such as reactions within a year of 
testing, historical treatment with epinephrine, and more severe hypersensitivity with 
respiratory system involvement or angioedema (Table 4). In our multivariate analysis, 
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direct amoxicillin challenge was associated with nonsignificant increased odds of HSR. 
Female sex was associated with significant increased odds of an ADR. The history and 
test reactions of our patients was also simply compared to evaluate any similarities. There 
were 43 patients that had objective reactions (ADRs) during their allergy testing. 
Penicillin was the culprit drug in 29 patients that experienced ADRs, followed in 
frequency by amoxicillin for 9 patients, cephalosporins for 3 patients, and the remaining 
2 patients could not recall the culprit drug. Despite skin testing not provoking an allergic 
response in any patients, penicillin was the culprit drug for 23 patients that were skin 
tested and experienced an ADR. None of the direct oral challenge patients that 
experienced ADRs had historical reactions to amoxicillin. None of the 43 patients had a 
history of an allergic reaction requiring treatment with epinephrine. Just 5 patients had 
historical reactions within one year of their allergy testing and 31 patients’ reactions were 
greater than 10 years prior to their allergy testing. This comparison and evaluation of 
potential predictors of drug allergy strengthens the support for continued research in to 
drug allergy to better understand what causes these hypersensitivities. 
Allergy De-labeling 
The penicillin allergy was removed in 476 (93.5%) of patients overall:  405 (95.1%) of 
patients who received PST followed by oral challenge and 77 (92.8%) of patients who 
received direct amoxicillin challenge (p=0.42). 27 patients were not de-labeled following 
their allergy evaluation. Twelve of these 27 patients were determined to have a true 
allergy and directed to avoid penicillin and amoxicillin. There were 11 patients that did 
not have their allergy label removed, despite not having an ADR. 2 patients had 
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subjective symptoms that were treated with antihistamines, qualifying their reaction, 
retrospectively, as an HSR. These two patients were recommended to return for repeat 
testing. Two other patients with non-HSRs, both experienced itching, but neither required 
treatment, did not have their allergy label removed but had comments added to their 
allergy label, noting their subjective symptoms. Not all patients with HSRs were labeled 
as penicillin-allergic. 14 of the 26 HSRs were not considered truly penicillin-allergic (12 
ST and 2 oral challenge). Some objective symptoms did end up resolving on their own or 
with a single dose of an antihistamine. Of those 14, only 2 patients had subsequent 
reactions to a beta-lactam antibiotic, however, there is not follow-up data on all 14 
patients to check whether they were subsequently prescribed antibiotics. There were 12 
patients that had negative allergy testing and should have had their allergy removed but 
did not. Reasons for this discrepancy included allergist error, patient request to leave 
allergy labeled, the addition of a comment to the allergy section describing negative 
testing without removal of the allergy, or unknown reasons. Of those who should have 
had their allergy label removed (n=488), six months after testing occurred, the penicillin 
allergy remained removed in 461 (90.6%) of patients:  385 of whom were penicillin skin 
tested (83.5%) and 76 who received a direct oral challenge (16.5%) (p=0.51).  Penicillin 
allergies were reentered in 15 patients, with 5 (33.3%) having subsequent 
hypersensitivity.  However, erroneous entry (n=15), and unknown reentry reasons (n=10) 
occurred.  Erroneous reentries occurred by nurses, medical assistants, physicians 
including allergists, and trainees including allergy fellows. In the 6 months following 
their evaluation, only 1 patient had a subsequent reaction to a beta-lactam antibiotic. Due 
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to the lack of data for patients seen at outside hospitals, it is unknown how many total 
patients received subsequent treatment with a beta-lactam antibiotic. 
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TABLE 1 Demographics of patients that received skin testing and multistep 
challenge. The values provided in this table are counts for each variable with percentage 
in parentheses, unless otherwise noted. 
 
Number (%) 
Total          
 (n=509) 
Skin Test and 
Challenge 
(n=426) 
2-step  
Test Dose 
(n=83) 
P value 
Age(yrs), mean±SD 
     [ 95% CI] 
49.5 ± 19.1 
[47.8, 51.1] 
  49.4 ± 19.0 
[47.5, 51.2] 
  50.0 ± 19.7 
[45.7, 54.3] 
0.789 
Female patients 369 (72.5)  318 (74.6) 51 (61.4) 0.020 
Race     0.404 
White 439 (86.2) 363 (85.2) 76 (91.6)  
Hispanic  17 (3.3) 15 (3.5) 2 (2.4)  
Black  11 (2.2) 11 (2.6) 0 (0.0)  
Asian 22 (4.3) 18 (4.2) 4 (4.8)  
Unknown 20 (3.9) 19 (4.5) 1 (1.2)  
Drug Allergy 
    
0 
184 (36.1) 154 (36.2) 30 (36.1) 1.000 
1 114 (22.4) 97 (22.8) 17 (20.5) 0.774 
2 73 (14.3) 58 (13.6) 15 (18.1) 0.305 
3 44 (8.6) 36 (8.5) 8 (9.6) 0.673 
>3 94 (18.5) 81 (19.0) 13 (15.7) 0.539 
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TABLE 2 Historical drug reactions. This table describes the culprit drug, reaction 
system involved, treatment provided (if any), and time from reaction to drug allergy 
evaluation. Multiple reaction systems may have been involved in historical reactions, 
patients were counted multiple times if they experienced multi-system involvement.  
 
Number (%) 
Total 
(n=509) 
Skin Test 
and 
Challenge 
 (n=426) 
2-step Test 
Dose 
(n=83) 
P value 
    History drug name 
    
Penicillin 352 (69.2) 296 (69.5) 56 (67.5) 0.815 
Amoxicillin 121 (23.8) 100 (23.5) 21 (25.3) 0.778 
Cephalosporin 17 (3.3) 14 (3.3) 3 (3.6) 0.747 
Ampicillin 5 (1.0) 5 (1.2) 0 (0.0) 1.000 
Piperacillin 3 (0.6) 2 (0.5) 1 (1.2) 0.414 
Unknown 11 (2.2) 9 (2.1) 2 (2.4) 0.697 
    Reaction system 
    
Cutaneous 401 (72.5) 349 (74.3) 52 (62.7) 0.040 
Angioedema 48 (8.7) 47 (10.0) 1 (1.2) 0.005 
Respiratory 31 (5.6) 29 (6.2) 2 (2.4) 0.205 
GI 16 (2.9) 13 (2.8) 3 (3.6) 0.719 
Unknown 57 (10.3) 32 (6.8) 25 (30.1) <0.001 
    Treatment given 
    
Antihistamines 53 (10.2) 48 (11.0) 5 (6.0) 0.235 
Steroids 12 (2.3) 12 (2.8) 0 (0.0) 0.230 
Medical Care 11 (2.1) 11 (2.5) 0 (0.0) 0.226 
Epinephrine 6 (1.2) 6 (1.4) 0 (0.0) 0.596 
Fluids 1 (0.2) 0 (0.0) 1 (1.2) 0.162 
Other Medication 3 (0.6) 2 (0.5) 1 (1.2) 0.412 
Unknown  433 (83.4) 356 (81.8) 77 (91.7) 0.040 
     Reaction History period 
    
Within 1 year 37 (7.3) 32 (7.5) 5 (6.0) 0.818 
More than 10 years 370 (72.7) 313 (73.5) 57 (68.7) 0.445 
Unknown 102 (20.0) 81 (19.0) 21 (25.3) 0.230 
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TABLE 3 Adverse Reactions and Hypersensitivity Reactions Resulting from 
Penicillin Allergy Testing.  
Number (%) 
All patients 
(n=509) 
 
Penicillin 
skin tested 
patients 
(n=426) 
 
Direct 
amoxicillin 
challenge 
patients 
(n=83) 
 
P-value* 
Adverse drug reactions 43 (8.5) 36 (8.5) 7 (8.4) 1.0 
Hypersensitivity 
reactions 
26 (5.1) 21 (4.9) 5 (6.0) 0.59 
Timing     
   Immediate reaction 18 (3.5) 15 (3.5) 3 (3.6) 1.0 
   Delayed reaction 8 (1.6) 6 (1.4) 2 (2.4) 0.62 
Signs and symptoms    0.29 
    Erythema 18 (3.5) 15 (3.5) 3 (3.6) 1.0 
    Itching 13 (2.6) 10 (2.4) 3 (3.6) 0.45 
    Rash 4 (0.8) 3 (0.7) 1 (1.2) 0.51 
    Hives 1 (0.2) 0 (0.0) 1 (1.2) 0.16 
    Difficulty swallowing 3 (0.6) 3 (0.7) 0 (0.0) 1.0 
    Gastrointestinal   
    symptoms 
2 (0.4) 1 (0.2) 1 (1.2)           0.30 
    Other 6 (1.18) 5 (1.2) 1 (1.2) 1.0 
Treatment Administered     
   Antihistamines 16 (3.1) 12 (2.8) 4 (4.8) 0.31 
   Corticosteroids 4 (0.8) 2 (0.5) 2 (2.4) 0.13 
   Epinephrine 2 (0.4) 1 (0.2)  1 (1.2)  0.30 
Non-hypersensitivity 
reactions (subjective 
symptoms) 
17 (3.3) 15 (3.5) 2 (2.4) 1.0 
    Itching                                                                    6 (1.2) 5 (1.2) 1 (1.2) 1.0 
    Difficulty swallowing 3 (0.6) 2 (0.5) 1 (1.2) 0.41 
    Rash 1 (0.2) 1 (0.2) 0 (0.0) 1.0 
   Gastrointestinal 
symptoms 
1 (0.2) 0 (0.0) 1 (1.2) 0.16 
Allergy documentation      
   Allergy label removed, 
Initial 
482 (94.7) 405 (95.1) 77 (92.8) 0.42 
   Allergy label removed, 6 
months 
461 (90.6) 385 (90.4) 76 (91.6) 0.73 
* Chi-squared test was used when sample size was greater than or equal to 30 and Fisher’s 
Exact test when expected cell number was less than 30 
T-test was used for continuous variables (age) 
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Table 4. Predictors of adverse drug reactions and hypersensitivity reactions 
 
Adverse Drug Reactions Odds ratio [95% CI]* P-value 
Age 1.01 [0.99, 1.03] 0.48 
Female 2.67 [1.00, 7.10] 0.050 
White  1.28 [0.46, 3.55] 0.64 
Number of other drug allergies  
(0 =ref) 
  
   1 2.43 [0.89, 6.60] 0.37 
   2 1.31 [0.36, 4.73] 0.40 
   ≥ 3 3.74 [1.46, 9.57] 0.008 
Incident reaction 1 year ago or less 2.19 [0.73, 6.52] 0.16 
Aminopenicillin as penicillin culprit 0.87 [0.38, 2.01] 0.74 
Respiratory symptoms with incident 
reaction  
1.28 [0.35, 4.67] 0.71 
Angioedema with incident reaction 1.14 [0.41, 3.23] 0.80 
Unknown incident reaction 0.55 [0.15, 1.99] 0.37 
Evaluation method direct challenge 1.23 [0.50, 3.05] 0.65 
Hypersensitivity Reactions Odds ratio [95% CI]* P-value 
Age  1.00 [0.98, 1.03] 0.81 
Female  2.91 [0.83, 10.26] 0.096 
White  2.33 [0.51, 10.80] 0.28 
Number of other drug allergies   
 1 3.85 [1.12, 13.27] 0.097 
 2 1.79 [0.38, 8.53] 0.70 
 ≥ 3 3.17 [0.91, 11.11] 0.27 
Incident reaction 1 year ago or less  2.64 [0.77, 9.12] 0.12 
Aminopenicillin as penicillin culprit  1.07 [0.40, 2.88] 0.90 
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Respiratory symptoms with incident 
reaction  
2.82 [0.74, 10.73] 0.13 
Angioedema with incident reaction  1.23 [0.33, 4.57] 0.76 
Unknown incident reaction  0.30 [0.04, 2.42] 0.26 
Evaluation method direct challenge 1.73 [0.59, 5.06] 0.32 
Non-Hypersensitivity Reactions 
(subjective symptoms or 
intolerances) 
Odds ratio [95% CI]* P-value 
Age  1.01 [0.98, 1.04] 0.47 
Female  2.26 [0.49, 10.47] 0.30 
White  0.62 [0.16, 2.37] 0.49 
Number of other drug allergies   
 1  0.88 [0.14, 5.50] 0.58 
 2 0.70 [0.07, 7.06] 0.47 
 ≥ 3 3.90 [0.97, 15.61] 0.008 
Incident reaction 1 year ago or less  1.23 [0.14, 10.87] 0.85 
Aminopenicillin as penicillin culprit  0.54 [0.11, 2.59] 0.44 
Respiratory symptoms with incident 
reaction  
- - 
Angioedema with incident reaction  1.04 [0.21, 5.00] 0.97 
Unknown incident reaction  0.96 [0.20, 4.74] 0.96 
Evaluation method direct challenge 0.70 [0.15, 3.38] 0.66 
*Multivariable logistic regression model results 
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DISCUSSION 
Evaluating penicillin allergies is an important step in antibiotic stewardship and can 
increase the utilization of safe, inexpensive, and preferred antibiotics. Allergic drug 
reactions, of any severity, often lead to the unnecessary – and sometimes permanent – 
avoidance of culprit medications. Allergy evaluation by skin testing and oral challenge is 
a safe and effective way to assess these patients and determine reported versus true 
penicillin allergies. We describe an outpatient penicillin allergy risk-stratification 
pathway at the Massachusetts General Hospital to safely evaluate patients with possible 
IgE-mediated penicillin allergies. Patients were referred for outpatient testing from 
primary care providers, infectious diseases clinicians, surgeons for preoperative testing, 
obstetricians for predelivery testing, and hospital-based teams as discharged inpatients.  
 
The results of the implementation of this pathway provide additional evidence for the 
safety of direct amoxicillin challenges in appropriately selected low risk patients. We 
observed a 6% HSR rate in 83 patients with low-risk penicillin allergy histories, a notably 
higher frequency than prior low-risk direct challenge reports (1.3-2.6%). This 
discrepancy could be attributed to different criteria for determination of an HSR. Our 
allergists were restricted to the use of EHR review to determine HSR, this could have 
inflated the number of HSRs compared to prospective review. It is interesting to note that 
despite the 36 HSRs we encountered, none of the skin tested patients experienced any 
objective reaction during the skin testing phase of their testing, all reactions occurred 
during the oral challenge. This is an interesting outcome because though skin testing is 
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thought to be the preferred method of testing for immediate-type hypersensitivity, it has 
recently been considered that skin testing might not accurately predict penicillin allergy.40 
Due to the number of HSRs to amoxicillin challenge, but not to the skin testing reagents, 
our research group is considering alternate reagents or determinates for skin testing, such 
as the addition of ampicillin or amoxicillin prick testing. This would be especially 
interesting considering one-quarter of the patients evaluated reported a historic 
aminopenicillin (ampicillin or amoxicillin) allergy. Ideally, the use of alternate 
determinates will identify hypersensitivities in the epi-cutaneous phase of the allergy 
evaluation before the oral challenge phase, that can produce more severe and pervasive 
reactions. The data also motivate our expansion of PST to those with recent anaphylaxis 
and/or prior positive PST (Figure 4). Though ST did not avert a single HSR it is 
nonetheless advisable for patients with higher risk allergy histories, pregnant patients, 
and patients with tenuous cardiac or pulmonary status.  
 
In this cohort, there were a handful of patients that experienced subjective symptoms 
such as difficulty swallowing or chest tightness without any objective signs or symptoms. 
The prevalence of subjective symptoms may support the addition of a placebo-controlled 
study to determine how many reactions during drug allergy testing are not 
immunologically based. Placebo-controlled challenges are standard in food allergy 
evaluation, especially in the research setting, and may have a similar benefit in drug 
allergy testing. Such a study might involve multiple steps of amoxicillin testing with an 
additional dose of placebo.18 This would ensure patients are informed that they are 
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receiving placebo as a part of their drug allergy evaluation, while allowing providers to 
determine the potential contribution of a patient’s stress or anxiety regarding allergy 
evaluation.  
 
Penicillin allergy labels remained in 28% of patients despite negative testing, and 38% 
have had erroneous redocumentation. We identified more modest deficiencies in 
penicillin allergy label removals and erroneous reentries (2% each), with no differences 
by penicillin allergy evaluation method. 
 
There were a few limitations to our study, such as only evaluating patients in a single 
outpatient allergy clinic. Utilizing a single site may have reduced the generalizability of 
our study. Because the outpatient clinic generally captures healthier patients, special 
considerations should be taken into account when assessing inpatient populations. 
Additionally, we did not include patients that were considered high-risk, based on Figure 
1. Another potential issue with generalizability is the criteria used for HSR classification. 
Though classification was performed by two allergists, they were limited to solely the 
description of the test reaction found in the EHR. Additionally, for delayed reactions, 
symptoms were reported by the patient via email or phone call, without a physician’s 
visual assessment. For these reasons, prospective identification and execution of this type 
of study is preferred. Many of the patients seen in our clinic for drug allergy testing are 
only seen for short periods of time or for a single evaluation, then resume care with a 
primary care physician, surgeon, or obstetrician. Therefore, we lack the longitudinal 
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follow-up data for these patients that would give insight into their long-term health 
related to their drug allergy. To address this limitation, we have started a drug allergy 
registry study that will allow us to collect data on drug allergy patients for 5 years 
following their evaluation. We will collect information on reaction history, record results 
of the evaluation in our allergy clinic, and follow-up with them periodically regarding 
prescriptions and reactions. This project will give us a picture of our patients’ health over 
time and hopefully help allergists better understand the natural history and epidemiology 
of drug allergy.  
 
In summary, thorough allergy history documentation can allow providers to risk-stratify 
patients into high-, intermediate-, or low-risk groups and proceed with allergy evaluation 
utilizing the safest standard of testing. We suggest direct challenges can be considered for 
appropriately selected low-risk patients presenting for penicillin allergy evaluation. 
Expansion of direct challenges facilitates penicillin allergy evaluations at a reduced 
expense, with savings of $127, accounting for personnel, consumables and space costs 
when ST is excluded.4 The implementation and up-front cost of such a risk-stratification 
protocol or other ASP can save patients, providers, and institutions money in the long-
term that would have been spent on alternative antibiotics. Finally, we outline a penicillin 
allergy evaluation tool that can be utilized in the outpatient setting to provide patients 
with increased autonomy when antibiotics are indicated and reduction in spending for all 
parties involved in drug allergy care. 
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Figure 4. New proposed risk-stratification for Massachusetts General Hospital 
Allergy Associates 
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Figure 4. New proposed risk-stratification for Massachusetts General Hospital 
Allery Associates.
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